hi continue visiting your profile
do you want to Log Out ?
AnyGenes

Insulin resistance.  What is insulin resistance pathway?

Insulin resistance pathway (IR) refers to the body's resistance to the effects of insulin on glucose uptake, metabolism, or storage.

  • Insulin signaling

Insulin is a peptide hormone produced by the beta cells in the pancreas. It plays a crucial role in maintaining the balance of glucose and lipids in the body.

Insulin signaling maintain glucose balance by reducing the production of glucose in the liver through decreased gluconeogenesis and glycogenolysis. As a result, the uptake of glucose in muscle and fat tissues increases. Insulin is also essential for lipid metabolism, as it stimulates lipid production in both the liver and fat cells. This by inhibiting the release of fatty acids from triglycerides in muscle and fat tissues.

In normal conditions, increased plasma glucose levels lead to increased insulin secretion and circulating insulin levels. This stimulates glucose transfer into peripheral tissues and inhibiting hepatic gluconeogenesis.

The biological effects of insulin occur when it attaches to its membrane receptors, insulin receptor (INSR). This activation triggers specific adapter proteins like insulin receptor substrate (IRS), Src-homology 2 (SH2), protein-tyrosine phosphatase 1B (PTP1B), PI3-kinase (PI3K), and different AKT isoforms. This initiates insulin signaling, leading to glucose homeostasis.

Various factors, like changes in receptor expression, ligand binding, phosphorylation states, and kinase activity, contribute to the different characteristics of insulin receptor (IR) phenotypes.

Akt activation has multiple downstream targets that produce distinct signaling responses in target tissues. Among them, GLUT4, which facilitates glucose uptake in skeletal muscle and white adipose cells when stimulated by insulin (1).

An integrated physiological signaling on different target tissues insulin resistance pathway.

 
An integrated physiological signaling on different target tissues insulin resistance (1)
.

Adipogenesis may lead to obesity, which causes many complications such as type 2 diabetes, high blood pressure, and cardiovascular disease.  What causes insulin resistance?

In human, insulin resistance associates with faulty insulin signaling. This occurs through various mechanisms. Including, storage of lipids, mitochondria dysfunction, and increased activity of stress-activated protein c-Jun-N-terminal-kinase (JNK). In addition to Endoplasmic reticulum (ER) stress, Amino acids and Low-grade inflammation.

In addition to metabolites, other factors and circumstances that can lead to insulin resistance. They include cytokines and chemokines ( tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-1β, and monocyte chemoattractant protein-1). In addition to Adipokines(adiponectin, leptin, chemerin, resistin, visfatin and vaspin), myokines, hepatokines, microRNAs or exosomes (4).
Altered interorgan crosstalk underlying the development of insulin resistance and possible therapeutic strategies

 
Altered interorgan crosstalk underlying the development of insulin resistance and possible therapeutic strategies (4)
.

Adipogenesis may lead to obesity, which causes many complications such as type 2 diabetes, high blood pressure, and cardiovascular disease.  Insulin resistance and diseases

Insulin resistance (IR) occurs when the body requires higher levels of insulin than usual to achieve a normal response. This results in hyperinsulinemia and impaired glucose tolerance. This leads to various groups of disorders. Among them, obesity, diabetes, metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease, heart disease, polycystic ovary syndrome (PCOS), and cancer..

Numerous studies have investigated the relationship between Alzheimer's disease and related disorders and insulin resistance in the brain and peripheral tissues (1,2).
(1) Li M, et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. (2022);7(1):216.
(2) Kellar D, et Craft S. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. (2020);19(9):758-766.
(3) Takano C, et al. Insulin Resistance in Mitochondrial Diabetes. Biomolecules. (2023);13(1):126.
(4) Mastrototaro L, et Roden M. Insulin resistance and insulin sensitizing agents. Metabolism. (2021);125:154892.

  • Biomarker list

You can check the biomarker list included in this pathway, see below:

For more information on prices, please click here
Quitter la version mobile